Takeda To Purchase IDM Pharma To Boost Oncology Business
This article was originally published in PharmAsia News
Takeda Pharmaceutical May 18 announced a buyout plan to acquire U.S. biopharmaceutical company IDM Pharma. Takeda plans to pay $75 million to obtain all outstanding shares of the Nasdaq-listed company. IDM has obtained approval in the EU for Mepact (mifamurtide), the first treatment approved for osteosarcoma. Through the buyout, Takeda plans to market the drug through marketing branches in Europe and expand its oncology business in the European market. (Click here for more - Japanese language
You may also be interested in...
P&G's decision to offload its Haliborange children's supplement line will not lead to reduced competition in the UK market, according to the regulator.
Fresenius Kabi’s Diprivan sedative was added to the US FDA’s drug shortage list in April as the COVID-19 pandemic peaked. A long-term committed purchasing agreement signed between the German firm and Premier Inc. will guarantee adequate supply and manage any future surges, the US hospitals group believes.
CanSino plans to start a Phase III study soon for its candidate with a 40,000 enrollment target, discloses its co-founder.